Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors

Cellular and Molecular Neurobiology

Volumn 19, Issue 4, 1999, Pages 443-466

  DeVane, C Lindsay ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Citalopram; Cytochrome P450; Fluoxetine; Fluvoxamine; Metabolism; Paroxetine; Pharmacokinetics; Selective serotonin reuptake inhibitors; Sert raline

Indexed keywords

CITALOPRAM; CYTOCHROME P450; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG URINE LEVEL; ENZYME INHIBITION; PRIORITY JOURNAL; REVIEW; STEREOCHEMISTRY;

AGE FACTORS; ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANXIETY; DEPRESSION; DRUG INTERACTIONS; HUMANS; SEROTONIN UPTAKE INHIBITORS; SEX FACTORS;

EID: 0032980470     PISSN: 02724340     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006934807375     Document Type: Review

References (122)

1. Altamura, A. C., Moro, A. R., and Percudani (1994). Clinical pharmacokinetics of fluoxetine. Clin. Pharmacokinet. 26:201-214.
2. Altshuler, L. L., Burt, V. K., McMullen, M., and Hendrick, V. (1995). Breastfeeding and sertraline: a 24-hour analysis. J. Clin. Psychiatry 56:243-245.
3. Aronoff, G. R., Bergstrom, R. F., Pottratz, S. T., Sloan, R. S., Wolen, R. L., and Lemberger, L. (1984). Fluoxetine kinetics and protein binding in ormal and impaired renal function. Clin. Pharmacol. Ther. 36:138-144.
4. Baumann, P. (1992). Clinical pharmacokinetics of citalopram and other selective serotonergic III reuptake inhibitors. Int. Clin. Psychopharmacol. 6 (Suppl. 5):13-20.
5. Baumann, P. (1996). Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin. Pharmacokinet. 31:444-469.
6. Baumann, P., Nil, R., Souche, A., Montaldi, S., Baettig, D., Lambert, S., Uehlinger, C., Kasas, A., Amey, M., and Jonzier-Perey, M. (1996). A double-blind placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: A clinical pharmacokinetic, and pharmacogenetic investigation. J. Clin. Psychopharmacol. 16:307-314.
7. Bealsey, C. M., Jr., Bosomworth, J. C., and Wernicke, J. F. (1990). Fluoxetine: Relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacol. Bull. 26:18-24.
8. Benfield, P., and Ward, A. (1986). Fluvoxamine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 32:313-334.
9. Bergstrom, R. F., van Lier, R. B. L., Lemberger, L., and Tenbarge, J. L. (1986). Absolute bioavailability of fluoxetine in beagle dogs. Abstr. Am. Pharm. Assoc. Acad. Pharm. Sci. 16:126.
10. Bergstrom, R. F., Lemberger, L. Farid, N. A., and Wolen, R. L. (1988a). Clinical pharmacology and pharmacokinetics of fluoxetine: A review. Br. J. Psychiatry 153 (Suppl. 3):47-50.
11. Bergstrom, R. F., et al. (1988b). Relative bioequivalence of a fluoxetine oral solution versus the marketed capsule. Pharm. Res. 7 (Suppl. 3):158.
12. Bjerkenstedt, L., Flyckt, L., Fredrickson Overø, K., and Lingjaerde, O. (1985). Relationship between clinical effects, serum drug concentrations and serotonin uptake inhibition in depressed patients treated with citalopram. Eur. J. Clin. Pharmacol. 28:553-557.
13. Bloomer, J. C., Woods, F. R., Haddock, R. E., Lennard, M. S., and Tucker, G. T. (1992). The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br. J. Clin. Pharmacol. 33:521-523.
14. Brett, M. A., Dierdorf, H.-D., Zussman, B. D. and Coates, P. E. (1987). Determination of paroxetine in human plasma, using high-performance liquid chromatography with fluorescence detection. J. Chromatogr. B Appl. 419:438-444.
15. Brosen, K., Skjelbo, E., Rasmussen, B. B., Poulsen, H. E., and Loft, S. (1993). Fluvoxamine is a potent inhibitor of cytochrome P450 1A2. Biochem. Pharmacol. 45:1211-1214.
16. Caccia, S., Cappi, M., Francasso, C., and Garattini, S. (1990). Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. Psychopharmacology 100: 509-514.
17. Carrillo, J. A., Dahl, M-L., Svensson, J.-O., Alm, C., Rodríguez, I., and Bertilsson, L. (1996). Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin. Pharmacol. Ther. 60:183-190.
18. Ceccherini-Nelli Guidi, L. (1993). Fluoxetine: The relationship between response, adverse events, and plasma concentrations in the treatment of bulimia nervosa. Int. Clin. Psychopharmacol. 8:311-313.
19. Classen, V. (1983). Review of the animal pharmacology and pharmacokinetics of fluvoxamine. Br. J. Clin. Pharmacol. 15 (Suppl. 3):349S-355S
20. Crewe, H. K., Lennard, M. S., Tucker, G. T., Woods, F. R., and Haddock, R. E. (1992). The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6 activity in human liver microsomes. Br. J. Clin. Pharmacol. 45:1211-1214.
21. Danish University Antidepressant Group (1990). Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J. Affect. Disord. 18:289-299.
22. De Bree, H., van der School, J. B., and Post, L. C. (1983). Fluvoxamine maleate: Disposition in man. Eur. J. Drug Metab. Pharmacokin. 8:175-179.
23. Dechant, K. L., and Clissold, S. P. (1991). Paroxetine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 41:225-253.
24. DeVane, C. L. (1994). Pharmacokinetics of the newer antidepressants: Clinical relevance. Am. J. Med. 97 (Suppl. 6A):13-23.
25. DeVane, C. L. (1997). The place of selective serotonin reuptake inhibitors in the treatment of panic disorder. Pharmacotherapy 17:282-292.
26. DeVane, O. L., and Jusko, W. J. (1983). Drug and metabolite concentrations combined in predicting steady-state concentrations from test doses. Biopharm. Drug Disp. 4:19-29.
27. de Vries, M. F., Raghoebar, M., Mathlener, J. S., and van Harten, J. (1992). Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects. Ther. Drug Monit. 14:493-498.
28. de Vries, M. H., van Harten, J., van Bemmel, P., and Raghoebar, M. (1993). Pharmacokinetics of fluvoxamine maleate after increasing single oral doses in healthy subjects. Biopharm. Drug Disp. 14:291-296.
29. DeWilde, J. E. M., and Doogan, D. P. (1982). Fluvoxamine and chlorimipramine in endogenous depression. J. Affect. Dis. 4:249-259.
30. DeWilde, J. E., Mertens, C., and Wakelin, J. S. (1983). Clinical trials of fluvoxamine vs. chlorimipramine with single and three times daily dosing. Br. J. Clin. Pharmacol. 15:4278-4318.
31. Dixit, V., Nguyen, H., and Dixit, V. M. (1991). Solid-phase extraction of fluoxetine and norfluoxetine from serum with gas chromatography-electron-capture detection. J. Chromatogr. 563:379-384.
32. Doyle, G. D., Lehar, M., Kelly, J. G., Byrne, M. M., and Clarkson, A. (1989). The pharmacokinetics of paroxetine in renal impairment. Acta Psychiatr. Scand. Suppl. 350:89-90.
33. Eap, C. B., Gaillard, N., Powell, K., and Baumann, P. (1996). Simultaneous determination of plasma levels of fluvoxamine and of the enantiomers of fluoxetine and norfluoxetine by gas chromatography-mass spectrometry. J. Chromatogr. Biomed. Appl. 682:265-272.
34. Fava, M., Rosenbaum, J. R., Cohen, L., Reiter, S., McCarthy, M., Steingard, R., and Clancy, K. (1992). High-dose fluoxetine in the treatment of depressed patients not responsive to a standard dose of fluoxetine. J. Affect. Dis. 25:229-234.
35. Foglia, J. P., Birder, L. A., and Perel, J. M. (1989). Determination of fluvoxamine in human plasma by high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. 495:295-302.
36. Foglia, J. P., Perel, J. M., Nathan, R. S., and Pollock, B. G. (1990). Therapeutic drug monitoring of fluvoxamine, a selective antidepressant. Clin. Chem. 36:1043 (abstract).
37. Fouda, H. G., and Ronfeld, R. A. (1987). Gas Chromatographic-mass spectrometric analysis and preliminary human pharmacokinetics of sertraline, a new antidepressant drug. J. Chromatogr. Biomed. Appl. 417:197-202.
38. Fuller, R. W., Snoddy, H. D., Krushinski, J. H., and Robertson, D. W. (1992). Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo. Neuropharmacology 31:997-1000.
39. Fuller, R. W., Hemrick-Luecke, S. K., Litterfield, E. S., and Audia, J. E. (1995). Comparison of desmethylsertraline with sertraline as a monoamine uptake inhibitor in vivo. Life Sci. 19:135-149.
40. Goodman, W. K., Price, L. H., Delgado, P. L., Palumbo, J., Krystal, J. H., Nagy, L. M., Rasmussen, S. A., Heninger, G. R., and Charney, D. S. (1990). Specificity of serotonin reuptake inhibitors in the treatment of obsessive compulsive disorder: Comparison of fluvoxamine and desipramine. Arch. Gen. Psychiatry 47:577-585.
41. Goff, D. C., Midha, K. K., Sarid-Segal, O., Hubbard, J. W., and Amico, E. (1995). A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology 117:417-423.
42. Gram, L. F. (1994). Fluoxetine. N. Engl. J. Med. 331:1354-1361.
43. Greenblatt, D. J., von Moltke, L. L., Schmider, J., Harmatz, J. S., and Shader, R. I. (1996). Inhibition of human cytochrome P450-3 A isoforms by fluoxetine and norfluoxetine: In vitro and in vivo studies. J. Clin. Pharmacol. 36:792-798.
44. Grimsley, S. R., and Jann, M. W. (1992). Paroxetine, sertraline, and fluvoxamine: New selective serotonin reuptake inhibitors. Clin. Pharm. 11:930-957.
45. Gupta, R. N. (1994). Column liquid Chromatographie determination of paroxetine in human serum using solid-phase extraction. J. Chromatogr. B Biomed. Appl. 661:362-365.
46. Gupta, R. N., and Dziurdzy, S. A. (1994). Therapeutic monitoring of sertraline. Clin. Chem. 40:498-499.
47. Gupta, R. N., and Steiner, M. (1990). Determination of fluoxetine and norfluoxetine in serum by liquid chromatography with fluorescence detection. J. Liquid Chromatogr. 13:3785-3797.
48. Haddock, R. E., Johnson, A. M., Langley, P. F., Nelson, D. R., Pope, J. A., Thomas, D. R., and Woods, F. R. (1989). Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites. Acta Psychiatr. Scand. 80 (Suppl. 350):24-26.
49. Hamelin, B. A., Turgeon, J., Vallee, F., Belanger, P.-M., Paquet, F., and LeBel, M. (1996). Role of CYP2D6 in the demethylation of fluoxetine in vivo. Clin. Pharmacol. Ther. 59:137.
50. Hartter, S., Wetzel, H., and Hiemke, C. (1992). Automated determination of fluvoxamine in human plasma by column switching high-performance liquid chromatography. Clin. Chem. 38:2082-2086.
51. Hartter, S., Hermes, B., Szegedi, A., and Hiemke, C. (1994). Automated determination of paroxetine and its main metabolite by column switching and on-line high-performance liquid chromatography. Ther. Drug Monit. 16:400-406.
52. Harvey, A. T., and Preskorn, S. H. (1996). Cytochrome P450 enzymes: Interpretation of their interactions with selective serotonin reuptake inhibitors. J. Clin. Psychopharmacol. 16:273-285.
53. Hurst, H. E., Jones, D. R., Jarboe, C. H., and deBree, H. (1981). Determination of clovoxamine concentration in human plasma by electron capture gas chromatography. Clin. Chem. 27:1210-1212.
54. Hyttel, J., Bogeso, K. P., Perregaard, J., and Sanchez, C. (1992). The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer. J. Neural Transm. 88:157-160.
55. Isenberg, K. E. (1990). Excretion of fluoxetine in human breast milk. J. Clin. Psychiatry 51:169.
56. Kasper, S., Dotsch, M., and Vieira, A. (1992). Plasma levels of fluvoxamine and maprotiline and clinical response in major depression. Pharmacopsychiatry 25:106.
57. Kasper, S., Dotsch, M., Kick, H., Vieira, A., and Möller, H.-J. (1993). Plasma concentrations of fluvoxamine and maprotiline in major depression: Implications of therapeutic efficacy and side effects. Eur. Neuropsychopharmacol. 3:13-21.
58. Kaye, C. M., Haddock, R. E., Langley, P. F., Mellows, G., Tasker, T. C. G., Zussman, B. D., and Greb, W. H. (1989). A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr. Scand. 80 (Suppl. 350):60-75.
59. Keck, P. E., Jr., and McElroy, S. L. (1992). Ratio of plasma fluoxetine to norfluoxetine concentrations and associated sedation. J. Clin. Psychiatry 53:127-129.
60. Kelly, M. W., Perry, P. J., Holstad, S. G., and Garvey, M. J. (1989). Serum fluoxetine and norfluoxetine concentrations and antidepressant response. Ther. Drug Monitor. 11:163-170.
61. Keogh, A., Spratt, P., McCosker, C., MacDonald, P., Mundy, J., and Kaan, A. (1995). Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N. Engl. J. Med. 333:628-633.
62. Ketter, T. A., Callahan, A. M., and Post, R. (1996). Nefazodone relief of alprazolam interdose dysphoria: A potential therapeutic benefit of 3A3/4 inhibition. J. Clin. Psychiatry 57:307.
63. Klok, C. J., Brouwer, G. J., VanPraag, H. M., and Doogan, D. (1981). Fluvoxamine and clomipramine in depressed patients. Acta Psychiatr. Scand. 64:1-11.
64. Kobayashi, K., Yamamoto, T., Chiba, K., Tani, M., Ishizaki, T., and Kuroiwa, Y. (1995). The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4′-hydroxylase activity in human liver microsomes. Br. J. Clin. Pharmacol. 40:481-485.
65. Koe, B. K., Weissman, A., Welch, W. M., and Browne, R. G. (1983). Sertraline, 1S,4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin. J. Pharmacol. Exp. Ther. 226:686-700.
66. Kragh-Sørensen, P., Overø, K. F., Petersen, O. L., Jensen, K., and Parnas, W. (1981). The kinetics of citalopram: Single and multiple dose studies in man. Acta Pharmacol. Toxicol. 48:53-60.
67. Krastev, Z., Terziivanov, D., Vlahov, V., Maleev, A., and Greb, W. H. (1989). The pharmacokinetics of paroxetine in patients with liver cirrhosis. Acta Psychiatr. Scand. 80 (Suppl. 350):91-92.
68. Kuhs, H., Schlake, H.-P., Rolf, L. H., and Rudolf, G. A. E. (1992). Relationship between parameters of serotonin transport and antidepressant plasma levels or therapeutic response in depressive patients treated with paroxetine and amitriptyline. Acta Psychiatr. Scand. 85:364-369.
69. Lane, R. M. (1996). Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int. Clin. Psychopharmacol. 11 (Suppl. 5):31-61.
70. Lantz, R. J., Farid, K. Z., Koons, J., Tenbarge, J. B., and Bopp, R. J. (1991). Determination of fluoxetine and norfluoxetine in human plasma by capillary gas chromatography with electron-capture detection. J. Chromatogr. B Biomed. Appl. 563:379-384.
71. Leinonen, E., Lepola, U., Koponen, H., and Kinnunen, I. (1996). The effect of age and concurrent treatment with other psychoactive drugs on serum concentration of citalopram measured with a nonenantioselective method. Ther. Drug Monit. 18:111-117.
72. Lester, B. M., Cucca, J., Andreozzi, L., Flanagan, P., and Oh, W. (1993). Possible association between fluoxetine hydrochloride and colic in an infant. J. Am. Acad. Child Adolesc. Psychiatry 32:1253-1255.
73. Lund Laursen, A., Mikkelsen, P. L., Rasmussen, S., and le Fèvre Honorè, P. (1985). Paroxetine in the treatment of depression: A randomized comparison with amitriptyline. Acta Psychiatr. Scand. 71: 249-255.
74. Luvox Product Information (1994). Solvey Pharmaceuticals, Inc.
75. Martensson, B., Nyberg, S., Toresson, G., Brodin, E., and Bertilsson, L. (1989). Fluoxetine treatment of depression. Acta Psychiatr. Scand. 79:586-596.
76. Matsui, E., Hoshino, M., Matsui, A., and Okahira, A. (1995). Simultaneous determination of citalopram and its metabolites by high performance liquid chromatography with column switching and fluores-cence detection by direct plasma injection. J. Chromatogr. 668:299-307.
77. Milne, R. J., and Goa, K. L. (1991). Citalopram. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depressive illness. Drugs 41:450-477.
78. Montgomery, S. A., Baldwin, D., Shah, A., Green, M., Fineberg, N., and Montgomery, D. (1990). Plasma level response relationships with fluoxetine and zimelidine. Clin. Neuropharmacol. 13 (Suppl. 1):S71-S73.
79. Nelson, J. C., Mazure, C. M., Bowers, M. B., Jr., and Jatlow, P. I. (1991). A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch. Gen. Psychiatry 48:303-307.
80. Nemeroff, C. B., DeVane, C. L., and Pollock, B. G. (1996). Antidepressants and the cytochrome P450 system. Am. J. Psychiatry 143:311-320.
81. Norman, R. T., Gupta, R. K., Burrows, G. D., Parker, G., and Judd, F. K. (1993). Relationship between antidepressant response and plasma concentrations of fluoxetine and norfluoxetine. Int. Clin. Psychopharmacol. 8:25-29.
82. Orsulak, P. J., Denny, J. P., Debus, J. R., Crowley, G., and Wittman, P. D. (1988). Determination of the antidepressant fluoxetine and its metabolite norfluoxetine in serum by reversed-phase HPLC, with ultraviolet detection. Clin. Chem. 34:1875.
83. Overmars, H., Scherpenisse, P. M., and Post, L. C. (1983). Fluvoxamine maleate: metabolism in man. Eur. J. Drug Metab. Pharmacokinet. 8:269-280.
84. Overø, K. F. (1978). Preliminary studies of the kinetics of citalopram in man. Eur. J. Clin. Pharmacol. 14:69-73.
85. Overø, K. F. (1982). Kinetics of citalopram in man: Plasma levels in patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 6:311-318.
86. Overø, K. F., Toft, B., Christophersen, L., and Gylding-Sabroe, J. P. (1985). Kinetics of citalopram in elderly patients. Psychopharmacology 86:253-257.
87. Parli, C. J., and Hicks, J. (1974). In vivo demethylation of Lilly 110140: 3-(p-Rifluoromethylphenoxy)-N-methyl-3-phenylpropylamine to an active metabolite - Lilly 103947. Fed. Proc. 33:560.
88. Perucca, E., Gatti, G., and Spina, E. (1994). Clinicalpharmacokinetics of fluvoxamine. Clin. Pharmacokinet. 27:175-190.
89. Peterson, E. N., Bechgaard, E., Sortwell, R. J., and Wetterberg, L. (1978). Potent depletion of 5HT from monkey whole blood by a new 5HT uptake inhibitor, paroxetine. Eur. J. Pharmacol. 52:115-119.
90. Peyton, A. L., Carpenter, R., and Rutkowski, K. (1991). The stereospecific determination of fluoxetine and norfluoxetine enantiomers in human plasma by high-pressure liquid chromatography with fluorescence detection. Pharm. Res. 8:1528-1532.
91. Potts, B. D., and Parli, C. J. (1992). Analysis of the enantiomers of fluoxetine and norfluoxetine in plasma and tissue using chiral derivatization and normal-phase liquid chromatography. J. Liq. Chromatogr. 15:665-681.
92. Raymond, P., Amey, M., Soncle, A., Lambert, S., Konrat, H., Eap, C. B., and Baumann, P. (1993). Determination of plasma levels of citalopram and its demethylated and deaminated metabolities by gas chromatography-mass spectrometry. J. Chromatogr. 616:221-228.
93. Rochat, B., Amey, M., Van Gelderen, H., Testa, B., and Baumann, P. (1995). Determination of the enantiomers of citalopram, its demethylated and propionic acid metabolites in human plasma by chiral HPLC. Chirality 7:389-395.
94. Rogowsky, D., Marr, M., Long, G., and Moore, C. (1994). Determination of sertraline and desmethylsertraline in human serum using copolymeric bonded-phase extraction, liquid chromatography and gas chromatography-mass spectrometry. J. Chromatogr. BioAppl. 655:138-141.
95. Ronfeld, R. A., Shaw, G. L., and Tremaine, L. M. (1988). Distribution and pharmacokinetics of the selective 5-HT uptake blockers sertraline in man, rat and dog. Psychopharmacology 96 (Suppl.): 269 (abstract).
96. Ruijten, H. M., De Bree, H., Borst, A. J. M., De Lange, N., Scherpenisse, P. M., Vincent, W. R., and Post, L. C. (1984). Fluvoxamine: Metabolic fate in animals. Drug Metab. Disp. 12:82-92.
97. Saletu, B., Grunberger, J., and Linzmayer, L. (1986). On central effects of serotonin re-uptake inhibitors: Quantitative EEG and psychometric studies with sertraline and zimelidine. J. Neural Transm. 67:241-266.
98. Schenker, S., Bergstrom, R. F., Wolen, R. L., and Lemberger, L. (1988). Fluoxetine disposition and elimination in cirrhosis. Clin. Pharmacol. Ther. 44:353-359.
99. Schweitzer, C., Spahn, H., and Mutschler, E. (1986). Fluorimetric determination of fluvoxamine or clovoxamine in human plasma after thin-layer chromatographic or high-performance liquid chromatographic separation. J. Chromatogr. 382:405-411.
100. Sindrup, S. H., Brøsen, K., Gram, L. F., Hallas, J., Skjelbo, E., Allen, A., Allen, G. D., Cooper, S. M., Mellows, G., Tasker, T. C. G., and Zussman, B. D. (1992a). The relationship between paroxetine and the sparteine oxidation polymorphism. Clin. Pharmacol. Ther. 51:278-287.
101. Sindrup, S. H., Brøsen, K., and Gram, L. F. (1992b). Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: Nonlinearity and relation to the sparteine oxidation polymorphism. Clin. Pharmacol. Ther. 51:288-195.
102. Sindrup, S. H., Brøsen, K., Hansen, M. G. J., Aaes-Jørgensen, T., Overø, K. F., and Gram, L. F. (1993). Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther. Drug Monitor. 15:11-17.
103. Skjelbo, E., and Brøsen, K. (1992). Inhibitors of imipramine metabolism by human liver microsomes. Br. J. Clin. Pharmacol. 34256-261.
104. Spigset, O., Carleborg, L., Hedenmalm, K., and Dahlqvist, R. (1995). Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin. Pharmacol. Ther. 58:399-403.
105. Stevens, J. C., and Wrighton, S. A. (1993). Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. J. Pharmacol. Exp. Ther. 226:964-971.
106. Szegedi, A., Wiesner, J., and Hiemke, C. (1995). Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine. J. Clin. Psychopharmacol. 15:141-143.
107. Tasker, T. C. G., Kaye, C. M., Zussman, B. D., and Link, C. G. G. (1989). Paroxetine plasma levels: Lack of correlation with efficacy or adverse events. Acta Psychiatr. Scand. 80 (Suppl. 350):152-155.
108. Torok-Both, G. A., Baker, G. B., Coutts, R. T., McKenna, K. F., and Aspeslet, L. J. (1992). Simultaneous determination of fluoxetine and norfluoxetine enantiomers in biological samples by gas chromatography with electron-capture detection. J. Chromatogr. B Biomed. Appl. 579:99-106.
109. Tremaine, L. M., and Joerg, E. A. (1989). Automated gas chromatographic-electron capture assay for the selective serotonin uptake blocker sertraline. J. Chromatogr. 496:423-429.
110. Tremaine, L. M., Welch, W. M., and Ronfeld, R. A. (1989). Metabolism and disposition of the 5-hydroxytryptamine uptake blocker sertraline in the rat and dog. Drug Metab. Disp. 17:542-550.
111. Tyrer, S. P., Marshall, E. F., and Griffiths, H. W. (1990). The relationship between response to fluoxetine, plasma drug levels, imipramine biding to platelet membranes and whole blood 5-HT. Prog. NeuroPsychopharmacol. Biol. Psychiatry 14:797-805.
112. Van der Meersch-Mougeot, V., and Diquet, B. (1991). Sensitive one-step extraction procedure for column liquid chromatographic determination of fluvoxamine in human and rat plasma. J. Chromatogr. 567:441-449.
113. Van Harten, J., Van Bemmel, P., Dobrinska, M. R., Ferguson, R. K., and Raghoebar, M. (1991). Bioavailability of fluvoxamine given with and without food. Biopharm. Drug Disp. 12:571-575.
114. Van Harten, J., Duchier, J., Devissaguet, J.-P., van Bemmel, P., de Vries, M. H. and Raghoebar, M. (1993). Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis after single-dose administration. Clin. Pharmacokinet. 7 24:177-182.
115. von Moltke, L. L., Greenblatt, D. J., Cotreau-Bibbo, M. M., Duan, S. X., Harmatz, J. S., and Shader, R. I. (1994). Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: A model system to predict drug interactions in vivo. J. Pharmacol. Exp. Ther. 268:1278-1283.
116. von Moltke, L. L., Greenblatt, D. J., Court, M. H., Duan, S. X., Harmatz, J. S., and Shader, R. I. (1995). Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: Comparison with other selective serotonin reuptake inhibitor antidepressants. J. Clin. Psychopharmacol. 15:125-131.
117. Warrington, S. J. (1992). Clinical implications of the pharmacology of sertraline. Int. Clin. Psychopharmacol. 6 (Suppl. 2):11-21.
118. Wiener, H. L., Kramer, H. K., and Reith, M. E. A. (1990). Separation and determination of sertraline and its metabolite, desmethylsertraline, in mouse cerebral cortex by reversed-phase high-performance liquid chromatography. J. Chromatogr. Biomed. Appl. 527:467-472.
119. Wong, S. H. Y., Dellafera, S. S., Fernandes, R., and Kranzler, H. (1990a). Determination of fluoxetine and norfluoxetine by high performance liquid chromatography. J. Chromatogr. 499:601.
120. Wong, D. T., Fuller, R. W., and Robertson, D. W. (1990b). Fluoxetine and its two enantiomers as selective serotonin uptake inhibitors. Acta Pharm. Nord. 2:171-180.
121. Wright, S., Dawling, S., and Ashford, J. J. (1991). Excretion of fluvoxamine in breast milk. Br. J. Clin. Pharmacol. 31:209.
122. Zoloft Prescribing Information (1996). Pfizer Pharmaceuticals, Inc.